Vera Therapeutics (VERA) News Today $18.95 -0.98 (-4.92%) Closing price 04:00 PM EasternExtended Trading$18.95 0.00 (0.00%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Vera Therapeutics (NASDAQ:VERA) Stock Price Up 5.7% - Time to Buy?Vera Therapeutics (NASDAQ:VERA) Trading Up 5.7% - Here's WhyMay 30 at 2:08 PM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.33 Consensus PT from AnalystsMay 29 at 1:43 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by AnalystsVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has received a consensus rating of "Buy" from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation anMay 27 at 1:17 AM | marketbeat.comCantor Fitzgerald maintains Vera Therapeutics at OverweightMay 26, 2025 | uk.investing.comBNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA)BNP Paribas Financial Markets purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 24,374 shares of the company's stock, valued at approximately $1,031,00May 23, 2025 | marketbeat.comWoodline Partners LP Acquires 201,573 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Woodline Partners LP raised its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 20.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,202,466 shares of the company's stock after acquiring an additional 201,573May 22, 2025 | marketbeat.comMarker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming WebcastMay 21, 2025 | nasdaq.comVestal Point Capital LP Acquires Shares of 1,075,000 Vera Therapeutics, Inc. (NASDAQ:VERA)Vestal Point Capital LP bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,075,000 shares of the company's stock, valued at approximately $45May 21, 2025 | marketbeat.comThornburg Investment Management Inc. Acquires 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Thornburg Investment Management Inc. raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 91.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59May 21, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 13.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 194,027 shares of the company's stock afMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)D. E. Shaw & Co. Inc. trimmed its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 42.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,476 shares of the company's stock after selling 55,990 sMay 21, 2025 | marketbeat.comMPM Bioimpact LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)MPM Bioimpact LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 257,788 shares of the company's stock, valued at approximately $10,902,00May 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Paradigm Biocapital Advisors LPParadigm Biocapital Advisors LP boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,437,339 shares of the compaMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Nicholas Investment Partners LPNicholas Investment Partners LP lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 49.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 106,805 shares of the company's stock aMay 16, 2025 | marketbeat.comEquities Analysts Offer Predictions for VERA FY2025 EarningsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Vera Therapeutics in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will eaMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Holdings Raised by Deutsche Bank AGDeutsche Bank AG raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 5.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 810,376 shares of the company's stock after buying anMay 16, 2025 | marketbeat.comNorthern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Northern Trust Corp boosted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 24.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 455,007 shares of the company's stock after acquiring an addiMay 16, 2025 | marketbeat.comVera Therapeutics: Huge Catalyst Upcoming For Kidney Disease DrugMay 15, 2025 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Orbimed Advisors LLCOrbimed Advisors LLC grew its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 9.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 742,572 shares of the company's stock after acquiring an addiMay 15, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Position Boosted by Integral Health Asset Management LLCIntegral Health Asset Management LLC lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 130.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,150,000 shares ofMay 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Cuts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Cubist Systematic Strategies LLC cut its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 44.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 56,921 shares of the company's stockMay 14, 2025 | marketbeat.comVera Therapeutics price target lowered to $55 from $60 at ScotiabankMay 12, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Releases Earnings Results, Misses Estimates By $0.06 EPSVera Therapeutics (NASDAQ:VERA - Get Free Report) issued its earnings results on Thursday. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period last year, the company posted ($0.56) earnings per share.May 12, 2025 | marketbeat.comAlgert Global LLC Acquires 15,386 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Algert Global LLC lifted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 66.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,550 shares of the company's stock after purchasingMay 12, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for VERA EarningsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Vera Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst A. He now anticipates that the company will post earnings pMay 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Raised by WedbushVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at Wedbush lifted their Q2 2025 EPS estimates for shares of Vera Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.71) per share for theMay 11, 2025 | marketbeat.comEvercore ISI Remains a Buy on Vera Therapeutics (VERA)May 10, 2025 | theglobeandmail.comWhat is Wedbush's Estimate for VERA Q1 Earnings?Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Vera Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst L. Chico anticipates that the company will earn ($0.95) per share for the quMay 10, 2025 | marketbeat.comQ2 Earnings Forecast for VERA Issued By HC WainwrightVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Vera Therapeutics in a research report issued on Monday, May 5th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($0.81) perMay 10, 2025 | marketbeat.comBalyasny Asset Management L.P. Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Balyasny Asset Management L.P. raised its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 119.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 385,425 shares of the compaMay 10, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 26.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 128,380 shares of the company's stock after acquiring an additional 26,519 shaMay 10, 2025 | marketbeat.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comQ1 Earnings Estimate for VERA Issued By HC WainwrightVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Monday, May 5th. HC Wainwright analyst A. He forecasts that the company will post eMay 9, 2025 | marketbeat.comCrestline Management LP Acquires 79,032 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Crestline Management LP lifted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 97.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,347 shares of the company's stock after acquiring an addMay 8, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Position Raised by Cutter Capital Management LPCutter Capital Management LP lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 23.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 212,696 shares of the company's stock after acquiring an additional 39,820 shares durinMay 8, 2025 | marketbeat.comHC Wainwright Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)HC Wainwright started coverage on shares of Vera Therapeutics in a research note on Monday. They set a "buy" rating and a $75.00 target price on the stock.May 7, 2025 | marketbeat.comVera Therapeutics shares fall as Q1 loss exceeds estimatesMay 6, 2025 | investing.comVera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Holdings Lessened by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC lessened its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 40.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 116,915 shares of the company's stock after selling 79,435 shares during the period.May 5, 2025 | marketbeat.comVera Therapeutics (VERA) Expected to Announce Earnings on ThursdayVera Therapeutics (NASDAQ:VERA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-vera-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Buy" from AnalystsVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus rating of "Buy" from the ten research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a sMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Boothbay Fund Management LLC bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 24,722 shares of the company's stock, vaMay 2, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by First Light Asset Management LLCFirst Light Asset Management LLC boosted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 78.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,261,246 shares of the company's stock after purchasing an additional 556,012 shares during the peApril 30, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 69,724 Vera Therapeutics, Inc. (NASDAQ:VERA)Raymond James Financial Inc. acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 69,724 shares of the company's stock, valued at approximatelyApril 30, 2025 | marketbeat.comVoya Investment Management LLC Buys 591,682 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Voya Investment Management LLC increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 572.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 695,091 shares ofApril 29, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Reduces Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Adage Capital Partners GP L.L.C. trimmed its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 65.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 480,000 shares of the companyApril 29, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,377,049 shares of the compApril 29, 2025 | marketbeat.comBarclays PLC Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Barclays PLC grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,148 shares of the company's stock afterApril 29, 2025 | marketbeat.comRenaissance Technologies LLC Makes New Investment in Vera Therapeutics, Inc. (NASDAQ:VERA)Renaissance Technologies LLC acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 35,700 shares of the company's stock, valued at approxApril 29, 2025 | marketbeat.comDecheng Capital LLC Reduces Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Decheng Capital LLC decreased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 28.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,767 shares of the company's stock after selling 20,000April 28, 2025 | marketbeat.com Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.690.88▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼65▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADMA Biologics News Today Vaxcyte News Today Rhythm Pharmaceuticals News Today Merus News Today Sarepta Therapeutics News Today Akero Therapeutics News Today Avidity Biosciences News Today ACADIA Pharmaceuticals News Today Cytokinetics News Today PTC Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERA Stock Free VERA Stock Alerts